Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 200

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Testosterone Supplementation in Heart Failure: A Meta-Analysis

Open access
Toma, Mustafa, McAlister, Finlay A., Coglianese, Erin E., Vidi, Venkatesan, Vasaiwala, Samip, Bakal, Jeffrey A., Armstrong, Paul W., Ezekowitz, Justin A.·2012·Circulation: Heart Failure
DOI 10.1161/circheartfailure.111.965632
Open this paper in CoChat — free account

Abstract

Background—: Low testosterone is an independent predictor of reduced exercise capacity and poor clinical outcomes in patients with heart failure (HF). We sought to determine whether testosterone therapy improves exercise capacity in patients with stable chronic HF. Methods and Results—: We searched Medline, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (1980–2010). Eligible studies included randomized controlled trials (RCTs) reporting the effects of testosterone on exercise capacity in patients with HF. Reviewers determined the methodological quality of studies and collected descriptive, quality, and outcome data. Four trials (n=198; men, 84%; mean age, 67 years) were identified that reported the 6-minute walk test (2 RCTs), incremental shuttle walk test (2 RCTs), or peak oxygen consumption (2 RCTs) to assess exercise capacity after up to 52 weeks of treatment. Testosterone therapy was associated with a significant improvement in exercise capacity compared with placebo. The mean increase in the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption between the testosterone and placebo groups was 54.0 m (95% CI, 43.0–65.0 m), 46.7 m (95% CI, 12.6–80.9 m), and 2.70 mL/kg per min (95% CI, 2.68–2.72 mL/kg per min), respectively. Testosterone therapy was associated with a significant increase in exercise capacity as measured by units of pooled SDs (net effect, 0.52 SD; 95% CI, 0.10–0.94 SD). No significant adverse cardiovascular events were noted. Conclusions—: Given the unmet clinical needs, testosterone appears to be a promising therapy to improve functional capacity in patients with HF. Adequately powered RCTs are required to assess the benefits of testosterone in this high-risk population with regard to quality of life, clinical events, and safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.111.965632

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 200

Metadata

Authors
Toma, M., McAlister, F. A., Coglianese, E. E., Vidi, V., Vasaiwala, S., Bakal, J. A., Armstrong, P. W., & Ezekowitz, J. A.
Venue
Circulation: Heart Failure
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2012-05
Volume
5
Issue
3
Pages
315-321
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
DOI
10.1161/circheartfailure.111.965632
OpenAlex
W2093954073
Cited by
200
References
14
FWCI
17.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Testosterone Supplementation in Heart Failure: A Meta-Analysis. https://app.cochat.ai/papers/10.1161/circheartfailure.111.965632
The paper
Toma, M., McAlister, F. A., Coglianese, E. E., Vidi, V., Vasaiwala, S., Bakal, J. A., Armstrong, P. W., & Ezekowitz, J. A. (2012). Testosterone Supplementation in Heart Failure: A Meta-Analysis. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.111.965632

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.